CHF116.52 pre-market: Novartis AG (NOVN.SW) on SIX 28 Jan 2026 watch earnings
We see NOVN.SW stock trading at CHF116.52 in pre-market action on the SIX as volume runs at 3,341,409.00 shares, making Novartis one of the most active names this session. The move keeps the price near its year high CHF117.14 and ahead of an earnings event on 04 Feb 2026. Market participants are watching valuation and catalysts: P/E sits at 20.26 and EPS at 5.75, while the healthcare sector shows stronger YTD performance. Meyka AI provides this pre-market snapshot and near-term context for traders and investors
Market snapshot: NOVN.SW stock pre-market moves
Novartis AG (NOVN.SW) is notable in pre-market trade on SIX with a last price of CHF116.52 and a one-day change of +0.64 (0.55%). Volume is 3,341,409.00 vs average volume 2,965,242.00, giving a relative volume of 1.13. The stock remains close to its year high of CHF117.14, keeping it among the most active Swiss healthcare names this morning.
News and catalysts: earnings and sector context
The next formal earnings announcement is scheduled for 04 Feb 2026, a near-term catalyst that could drive volatility and volume. Investors cite recent coverage on Investing.com and U.S.-listed commentary on MarketWatch as sources for liquidity and sentiment signals.
Sector strength matters: Healthcare in Switzerland has a YTD gain of 6.72%, which helps explain part of the demand for NOVN.SW stock today.
Fundamentals and valuation: earnings, cash flow and dividend
Novartis reports EPS 5.75 and a P/E of 20.26, a valuation below the Swiss healthcare sector average P/E of about 34.64, implying relative value versus peers. The company shows robust free cash flow per share at 9.39 and a dividend per share near 4.57, giving a yield around 3.00% on the current price.
Balance-sheet ratios support flexibility: debt-to-equity is 0.72 and interest coverage is 15.66, both consistent with an investment-grade profile for a major drug maker.
Technical and liquidity signals for traders
Technicals show short-term strength: RSI is 74.23 (overbought), MACD histogram is positive at 0.53, and the 50-day price average is CHF109.08 versus the current CHF116.52, indicating a strong uptrend. Average true range (ATR) is 1.69, offering a guidance band for intraday moves.
Liquidity is high: today’s volume 3,341,409.00 exceeds the 50-day average and supports tighter spreads, which benefits active traders monitoring pre-market momentum.
Meyka rating and model forecast for NOVN.SW stock
Meyka AI rates NOVN.SW with a score out of 100: 74.47 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not financial advice.
Meyka AI’s forecast model projects a near-term monthly target of CHF123.14, a quarterly level of CHF111.57, and a one-year level near CHF108.32. Versus the current CHF116.52, the monthly projection implies an upside of +5.68% and the one-year projection implies a downside of -7.02%. Forecasts are model-based projections and not guarantees.
Risks and strategy: what active traders should watch
Key risks include earnings execution on 04 Feb 2026, pricing pressure in generics for Sandoz, and regulatory headlines tied to drug approvals. Macroeconomic moves and FX shifts (CHF strength) can also compress margins.
For active strategies: monitor volume spikes, intraday RSI above 70, and the 50-day moving average at CHF109.08 as a technical support zone. Use position sizing to limit exposure around earnings.
Final Thoughts
Novartis AG (NOVN.SW) is a top pre-market mover on SIX at CHF116.52, trading with above-average liquidity and a close proximity to its year high. Fundamentals are solid: P/E 20.26, EPS 5.75, free cash flow per share 9.39, and a dividend yield near 3.00%. Technically the stock reads as short-term overbought with RSI 74.23, which raises the odds of a near-term pullback into the CHF109.08 50-day average on weakness. Meyka AI’s forecast model projects a monthly level of CHF123.14, implying a +5.68% upside from current levels; the one-year projection of CHF108.32 shows potential downside. Traders who focus on the “most active” strategy should watch earnings on 04 Feb 2026, volume confirmation, and whether the stock can hold the 50-day average. Our view frames NOVN.SW stock as attractively valued versus healthcare peers, but short-term volatility around earnings and technical overbought signals counsel controlled position sizing. Meyka AI provides this AI-powered market analysis to help frame risk and opportunity—forecasts are model-based and not guarantees.
FAQs
What is driving NOVN.SW stock pre-market activity today?
Pre-market interest in NOVN.SW stock stems from near-term earnings on 04 Feb 2026, a tight trading range near the year high CHF117.14, and higher-than-average volume of 3,341,409.00 shares that is drawing active traders to the name.
How does Novartis trade versus sector peers on valuation?
Novartis trades at P/E 20.26, below the Swiss healthcare sector average P/E of about 34.64, signaling relatively cheaper valuation versus peers while offering a roughly 3.00% dividend yield.
What price targets does Meyka AI show for NOVN.SW stock?
Meyka AI’s forecast model projects a monthly target of CHF123.14 (implied upside +5.68%) and a one-year projection of CHF108.32 (implied downside -7.02%). Forecasts are model-based projections and not guarantees.
What technical levels should traders watch in pre-market trading?
Traders should monitor RSI 74.23 (overbought), the 50-day average at CHF109.08 as immediate support, and intraday volume spikes above 2,965,242.00 average volume for breakout confirmation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
